JP2006527741A - 細胞遊走の阻害剤 - Google Patents

細胞遊走の阻害剤 Download PDF

Info

Publication number
JP2006527741A
JP2006527741A JP2006516231A JP2006516231A JP2006527741A JP 2006527741 A JP2006527741 A JP 2006527741A JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006516231 A JP2006516231 A JP 2006516231A JP 2006527741 A JP2006527741 A JP 2006527741A
Authority
JP
Japan
Prior art keywords
prommp
cells
integrin
mmp
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006516231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006527741A5 (enExample
Inventor
ステファニダキス，ミカエル
コイヴネン，エルッキ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTT Cancer Targeting Technologies Oy
Original Assignee
CTT Cancer Targeting Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030923A external-priority patent/FI20030923A7/fi
Priority claimed from FI20040616A external-priority patent/FI20040616A0/fi
Application filed by CTT Cancer Targeting Technologies Oy filed Critical CTT Cancer Targeting Technologies Oy
Publication of JP2006527741A publication Critical patent/JP2006527741A/ja
Publication of JP2006527741A5 publication Critical patent/JP2006527741A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2006516231A 2003-06-19 2004-06-21 細胞遊走の阻害剤 Withdrawn JP2006527741A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030923A FI20030923A7 (fi) 2003-06-19 2003-06-19 Leukosyytti-proMMP-9/beta2-integriinikompleksin inhibiittorit
FI20040616A FI20040616A0 (fi) 2004-04-29 2004-04-29 Solumigraation inhibiittorit
PCT/FI2004/000376 WO2004110478A1 (en) 2003-06-19 2004-06-21 Inhibitors of cell migration

Publications (2)

Publication Number Publication Date
JP2006527741A true JP2006527741A (ja) 2006-12-07
JP2006527741A5 JP2006527741A5 (enExample) 2007-08-02

Family

ID=33553915

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006516231A Withdrawn JP2006527741A (ja) 2003-06-19 2004-06-21 細胞遊走の阻害剤
JP2006516230A Withdrawn JP2006527740A (ja) 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006516230A Withdrawn JP2006527740A (ja) 2003-06-19 2004-06-21 白血球におけるｐｒｏＭＭＰ−９／β２インテグリン複合体の阻害剤

Country Status (3)

Country Link
EP (2) EP1644031A1 (enExample)
JP (2) JP2006527741A (enExample)
WO (2) WO2004110478A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507307A (ja) * 2008-11-04 2012-03-29 インデックス・ファーマシューティカルズ・アクチエボラーグ 多形核細胞の動員および／または遊走を減少させる化合物および方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595935A1 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
EP1924595A2 (en) * 2005-08-12 2008-05-28 Cartela R & D AB Novel peptides and uses thereof
GB2429012A (en) * 2005-08-12 2007-02-14 Cartela Ab Polypeptides capable of binding an integrin I-domain.
US8003110B1 (en) * 2011-01-24 2011-08-23 Matthias W. Rath Metalloproteinase oligopeptides and their therapeutic use
WO2018175749A2 (en) 2017-03-22 2018-09-27 Children's Medical Center Corporation Lrp1 binding agents and uses thereof
CN110691606A (zh) 2017-03-22 2020-01-14 儿童医学中心公司 Prss2抑制

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817750A (en) * 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
US20030022835A1 (en) * 1998-04-29 2003-01-30 Genesis Research And Development Corporation Limited Compositions isolated from skin cells and methods for their use
GB9809764D0 (en) * 1998-05-07 1998-07-08 Isis Innovation MMP-9 Gene polymorphisms
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
WO2003091391A2 (en) * 2002-04-23 2003-11-06 Duke University Atherosclerotic phenotype determinative genes and methods for using the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012507307A (ja) * 2008-11-04 2012-03-29 インデックス・ファーマシューティカルズ・アクチエボラーグ 多形核細胞の動員および／または遊走を減少させる化合物および方法

Also Published As

Publication number Publication date
EP1644031A1 (en) 2006-04-12
JP2006527740A (ja) 2006-12-07
EP1644032A1 (en) 2006-04-12
WO2004110478A1 (en) 2004-12-23
WO2004110477A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
Noh et al. Role of urokinase receptor in tumor progression and development
Brownstein et al. Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages
AU2003251233B2 (en) Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity
Stefanidakis et al. Intracellular and cell surface localization of a complex between αMβ2 integrin and promatrix metalloproteinase-9 progelatinase in neutrophils
CA2233670C (en) Mutant plasminogen activator-inhibitor type 1 (pai-1) and uses thereof
Rostagno et al. Chromosome 13 dementias
US20070003552A1 (en) Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
KR101154550B1 (ko) 폰 빌레브란트 인자 특이적 절단 효소에 대한 항체 및그것을 이용한 분석계
Talamagas et al. Abeta (1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP
AU783019B2 (en) Novel method and composition for inhibition of angiogenesis using antagonists based on MMP-9 and beta1 integrins
EP1644032A1 (en) Inhibitors of cell migration
EP1313504B1 (en) Methods and compositions for inhibiting angiogenesis
JP2852192B2 (ja) ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
US20070099839A1 (en) Inhibitors of cell migration
EDICINA The role of plasminogen activator receptor in cancer invasion and dormancy
CN114981661A (zh) 用于诊断与嗜中性粒细胞胞外陷阱相关的纤溶功能不全的方法
US7160858B2 (en) Methods and compositions for inhibiting angiogenesis
Altieri Interface between inflammation and coagulation
Reid Plasminogen activators and their inhibitor synthesized by human mesangial cells and other cell types
Involves Human Polymorphonuclear Leukocytes Adhere
Kelly A neutral protease of the neutrophil surface: role in the proteolysis of C-reactive protein and fibrinogen
ALTIERI and Coagulation
Leong The PAI-1-vitronectin-vimentin ternary complex: mechanism of extracellular assembly and role in transplant vasculopathy
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070618

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20071012